Cargando…
Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice
Neutrophils have been implicated in initiating and perpetuating systemic lupus erythematosus and the resultant kidney damage in lupus nephritis (LN) patients, in part through an excessive release of neutrophil serine proteases (NSPs). NSP zymogens are activated by dipeptidyl peptidase 1 (DPP1) durin...
Autores principales: | Chen, Kuan-Ju, Zhang, Jimin, LaSala, Daniel, Basso, Jessica, Chun, Donald, Zhou, Yuchen, McDonald, Patrick P., Perkins, Walter R., Cipolla, David C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10333524/ https://www.ncbi.nlm.nih.gov/pubmed/37441081 http://dx.doi.org/10.3389/fimmu.2023.1185727 |
Ejemplares similares
-
Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis
por: McDonald, Patrick P., et al.
Publicado: (2023) -
Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial
por: Cipolla, David, et al.
Publicado: (2023) -
The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species
por: Basso, Jessica, et al.
Publicado: (2023) -
Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis
por: Chalmers, James D., et al.
Publicado: (2022) -
Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults
por: Usansky, Helen, et al.
Publicado: (2022)